|
|
| Bio Nova International Pty Ltd |
| |
|
Bio Nova has more than 20 years experience in research, development, manufacturing and commercialisation of medical devices and one of the few commercially viable products based on tissue-engineering technology. The development pipeline contains several ground-breaking products based on tissue engineering. The current Omniflow II biosynthetic vascular prosthesis is a leading product for peripheral revascularisation and arteriovenous access.
- Distribution partners in Eastern Europe, the Middle East, Latin America and Asia
- Institutional investors
- Products suitable for joint commercialisation
The Omniflow II series of vascular prostheses is available for:
- Peripheral revascularisation
- Arteriovenous access
- Vascular repair
Biosynthetic materials manufactured through tissue-engineering technology combines the best properties of biological and synthetic materials. Biocompatibility allows integration into the body’s tissue structure whilst the synthetic component provides strength and durability. In the case of Omniflow II the biosynthetic design gives properties more similar to a live blood vessel than any other prosthesis on the market, providing the best value for the patient and the health care system.
www.bionova.com.au
 
| |
|
|
|
|
|
|
|
|
|
|